超早期远程缺血后适应在急性缺血性卒中血管内治疗中的随机临床试验
EnTRIPS多中心随机对照试验纳入270例大血管闭塞且血管内治疗后成功再通的急性缺血性卒中患者,在术后6小时内随机给予远程缺血后适应联合指南治疗或单纯指南治疗。90天功能独立率两组无显著差异(60.9% vs 57.8%,校正RR 1.07,95%CI 0.89-1.30,P=0.46),RIPC相关不良事件发生率为7.5%。
要点
- 超早期RIPC在EVT术后患者中安全,RIPC相关不良事件发生率7.5%。
- RIPC未显著改善90天功能独立率(校正RR 1.07,95%CI 0.89-1.30,P=0.46)。
- 该试验不支持EVT术后常规使用超早期RIPC改善功能预后。
核心结论
- 超早期RIPC对接受EVT的急性缺血性卒中患者是安全的,但未显著改善90天功能结局。
研究设计与样本
- EnTRIPS为多中心、随机、对照、结局评估者盲法的前瞻性临床试验,在中国8家医院开展。
- 纳入270例发病24小时内、大血管闭塞、接受EVT并成功再通的成人急性缺血性卒中患者。
- 患者在EVT后6小时内随机分为RIPC联合指南治疗组(n=135)或单纯指南治疗组(n=135)。
- RIPC使用袖带装置进行7天干预,每周期双侧上臂充气5分钟(180 mm Hg)后放气3分钟,共5个循环。
主要发现
- 268例(99.3%)完成试验,RIPC组133例、对照组135例;平均年龄65.5岁(SD 16.8),男性171例(63.8%)。
- 90天功能独立(mRS 0-2)率RIPC组为60.9%(81例),对照组为57.8%(78例)。
- 校正风险比为1.07(95%CI 0.89-1.30),P=0.46。
- RIPC相关不良事件发生于10/133例(7.5%),对照组无干预相关不良事件。
关键数值与推荐
- 主要结局为90天功能独立,定义为改良Rankin量表评分0-2分(范围0无症至6死亡)。
- 安全性结局为7天内RIPC相关不良事件发生率。
临床怎么用
- 对于EVT成功再通的急性缺血性卒中患者,超早期RIPC安全性可接受但未显示功能获益。
- 不推荐将超早期RIPC作为EVT术后的常规神经保护措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the neuroprotective potential of remote ischemic postconditioning (RIPC) has been reported, the efficacy and safety of ultra-early RIPC administered after endovascular treatment (EVT) in patients with acute ischemic stroke remain unclear. This study evaluated the efficacy and safety of ultra-early RIPC in patients with acute ischemic stroke undergoing EVT. METHODS: The EnTRIPS trial (Endovascular Treatment Combined With Remote Ischemic Postconditioning in Patients With Acute Ischemic Stroke) was a multicenter, randomized, controlled, outcome assessor-blinded, prospective clinical trial. The trial was conducted at 8 hospitals in China between April 12, 2021, and March 26, 2025. Eligible patients were adults with acute ischemic stroke due to large vessel occlusion who presented within 24 hours of symptom onset, underwent EVT, and achieved successful recanalization. A total of 270 eligible patients were randomized within 6 hours after EVT to receive either RIPC plus guideline-based therapy (n=135) or guideline-based therapy alone (n=135). RIPC was administered for 7 days using pneumatic devices consisting of 5 cycles of bilateral upper-arm cuff inflation (5 minutes at 180 mm Hg) followed by deflation (3 minutes). The primary outcome was functional independence at 90 days, defined as a modified Rankin Scale score of 0 to 2 (range, 0 [no symptoms] to 6 [death]). Safety outcomes included the incidence of RIPC-related adverse events within 7 days. RESULTS: Among 270 randomized patients, a total of 268 (99.3%) participants completed the trial, including 133 in the RIPC group and 135 in the control group (mean [SD] age, 65.5 [16.8] years; 171 [63.8%] men). At 90 days, functional independence was achieved in 81 (60.9%) patients in the RIPC group and 78 (57.8%) patients in the control group (adjusted risk ratio, 1.07 [95% CI, 0.89-1.30]; P=0.46). RIPC-related adverse events occurred in 10 of 133 (7.5%) patients, and no intervention-related adverse events occurred in the control group. CONCLUSIONS: Ultra-early RIPC is safe for patients with acute ischemic stroke treated with EVT, but it does not significantly improve the 90-day functional outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04581759.
引用
- Cheng Y, Chen W, Chang M, et al. Remote Ischemic Postconditioning in Endovascular Thrombectomy for Stroke: The EnTRIPS Randomized Clinical Trial. Stroke. 2026. PMID: 42267436. doi:10.1161/STROKEAHA.126.054857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。